Star Imaging And Path Lab Ltd (STARIMAGIN) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company reported a stable performance for FY26, with revenue growth of 6% and a significant 17% expansion in EBITDA, reflecting improved operational leverage and a better business mix.
- The B2C segment was the primary growth driver, expanding by 18%, while the B2B segment grew by 10% and the B2G segment remained stable.
- Management expressed strong confidence in achieving 25-30% growth in FY27, attributing the subdued FY26 performance to regulatory delays which have now been resolved.
- The company significantly improved its financial health, turning net cash positive and generating a strong operating cash flow of INR 23.4 crores, a substantial turnaround from a negative cash flow in the previous year.
- Strategic focus for FY27 remains on expanding the diagnostic center footprint in existing and new geographies, deepening specialized diagnostic capabilities, and pursuing additional Public-Private Partnership (PPP) contracts.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.